Related by context. All words. (Click for frequent words.) 65 anthracycline taxane 64 antiandrogen 64 pegylated liposomal doxorubicin 64 Targretin capsules 64 gemcitabine cisplatin 63 HealthStream Learning 63 Azactam 63 Aloxi injection 62 evaluating tivozanib 62 Alkeran 62 Hycamtin ® 62 postoperative chemotherapy 62 doxorubicin cyclophosphamide 62 carboplatin paclitaxel 62 placebo dexamethasone 62 concurrent chemoradiation 62 BLU U ® 62 pamidronate 62 Fludara ® 61 biologic DMARD 61 Peginterferon alfa 2b 61 Velcade bortezomib 61 paclitaxel Taxol R 61 dacarbazine chemotherapy 61 taxane chemotherapy 61 debulking surgery 61 lenalidomide Revlimid R 61 PDP MLR 61 OPANA franchise 61 castrate resistant 61 HER2 positive metastatic breast 61 relapsed MM 61 goserelin 61 VANTAS ® 61 ARCALYST ® 61 docetaxel chemotherapy 61 FOLFIRI alone 61 Kerastick ® 61 gemcitabine carboplatin 61 Programmer Paradise segment 61 paclitaxel chemotherapy 61 chlorambucil 61 sequentially 60 microbiological eradication 60 dacarbazine DTIC 60 Pegasys peginterferon alfa 2a 60 paclitaxel Taxol ® 60 prednisone prednisolone plus 60 mitoxantrone plus 60 thalidomide Thalomid 60 mitoxantrone chemotherapy 60 Clinical Diagnostics segment 60 flutamide 60 Fludara 60 ACR# responses 60 CYT# potent vascular disrupting 60 docetaxel Taxotere 60 oral hypoglycemic agent 60 Irinotecan 60 Thalomid ® 60 melphalan prednisone 60 rFSH 60 FOLFIRI 60 dexamethasone Decadron 60 PASI scores 60 Doxil ® 60 nonsmall cell lung cancer 60 KRAS mutations occur 60 Gliadel Wafer 60 5-FU/LV 60 refractory AML 60 increaseof 60 SCCHN 60 metastatic renal cell carcinoma 60 tenofovir emtricitabine 60 BLU U R 60 FROVA 60 sorafenib Nexavar ® 60 Electro Rent NASDAQ ELRC 59 preoperative chemotherapy 59 tumors GIST 59 Elitek 59 Kerastick 59 Blended ARPU 59 netsales 59 dacarbazine 59 Tumors shrank 59 papillary renal cell carcinoma 59 lipid lowering agents 59 OCF margin 59 LIDODERM 59 Fludarabine 59 anthracycline containing 59 raloxifene Evista 59 FUSILEV enhances 59 metastatic colorectal 59 docetaxel prednisone 59 ritonavir boosted atazanavir 59 LHRH agonists 59 metastatic RCC 59 paclitaxel carboplatin 59 Folfox 59 vinorelbine tartrate 59 underwent surgical resection 59 Thal Dex 59 SPRYCEL ® 59 THALOMID 59 mcg albinterferon alfa 2b 59 Specialty Engineered Alloys 59 TEB adjustment 59 refractory metastatic colorectal cancer 59 adalimumab Humira 59 oral diclofenac 59 Nisisco ® 59 Recurring royalties 59 Cytec Surface Specialties 59 Pemetrexed 59 Billable headcount 59 locoregional recurrence 59 Currency translation negatively impacted 59 Pfizer Camptosar 59 ER CHOP 59 stage IIIB 59 cetuximab Erbitux R 59 methotrexate therapy 59 5FU 58 anastrazole 58 TEMODAL 58 binary restenosis 58 non squamous NSCLC 58 Drug eluting stent 58 angiographic outcomes 58 FOLFOX6 58 epirubicin cyclophosphamide 58 prospectively stratified 58 estramustine 58 CHOP chemotherapy 58 metastatic SCCHN 58 3Q FY# 58 flattish sequentially 58 tyrosine kinase inhibitor TKI 58 idraparinux 58 panitumumab Vectibix R 58 pegylated interferon alpha 58 Neulasta ® 58 achieved ACR# 58 Erlotinib 58 clodronate 58 vincristine doxorubicin 58 undetectable HBV DNA 58 pharmacologically active isomer 58 Allovectin 7 ® 58 Sutent sunitinib 58 chemotherapy cisplatin 58 R sorafenib tablets 58 autologous SCT 58 telaprevir dosed 58 Prepaid churn 58 cytoreductive nephrectomy 58 OshKosh wholesale 58 trabectedin 58 oblimersen 58 advanced adenomas 58 neoadjuvant therapy 58 Interferon alfa 58 anthracyclines taxanes 58 intravesical therapy 58 HER2 amplified 58 Thrombin 58 regorafenib 58 prioryear 58 metastatic renal cell 58 receptor tyrosine kinase inhibitor 58 Panzem R NCD 58 Platinol ® cisplatin 58 advanced hepatocellular carcinoma 58 totaled EUR#.#m 58 Navelbine ® 58 stage IIIb IV 58 A1PI 58 #mg q8h 58 TYSABRI therapy 58 care regimens CCR 58 Medicare Advantage MLR 58 Camptosar ® 58 metastatic bladder 58 Additive Technologies 58 Wholesale Leathercraft 58 salmeterol fluticasone 58 hepatic metastases 58 mitomycin 58 colorectal liver metastases 58 Herceptin trastuzumab 58 saline placebo 58 intra arterial chemotherapy 58 plus prednisone prednisolone 58 piperacillin tazobactam 58 cyclophosphamide methotrexate 58 MGd 58 Paraplatin 58 ethambutol 58 allogeneic HSCT 58 Riluzole 58 Peg IFN 58 unresectable tumors 58 Contura MLB 57 Gemcitabine 57 BioGlue revenues 57 intravenous bisphosphonates 57 LUCENTIS r 57 HBeAg negative 57 9M FY# [002] 57 erlotinib Tarceva 57 Refractories segment 57 oral clodronate 57 Neulasta R 57 tumor xenograft models 57 epirubicin 57 recurrent NSCLC 57 radiotherapy RT 57 gastrointestinal stromal tumors 57 VELCADE melphalan 57 sameperiod 57 differentiated thyroid 57 KRAS wild 57 metastatic hormone refractory 57 complete cytogenetic response 57 novel emulsion formulation 57 PRESEPT study 57 Hectorol R 57 LIFO provision 57 peripheral sensory neuropathy 57 Granisetron 57 fluoropyrimidine 57 9M FY# [001] 57 radiochemotherapy 57 xanthine oxidase inhibitor 57 biliary tract cancer 57 MDS AML 57 cytotoxic therapy 57 plus aztreonam 57 trastuzumab Herceptin ® 57 totaled USD#.#m 57 achieved CCyR 57 topical gel formulation 57 unresectable 57 liposomal doxorubicin 57 8mg/kg 57 Gleevec imatinib mesylate 57 interferon alfa 2a 57 noninterest expense decreased 57 Engineered Products segment 57 Taxotere docetaxel 57 infusional 5-FU/LV 57 Ceplene/IL-2 57 pegfilgrastim 57 Temsirolimus 57 IV bisphosphonates 57 neoadjuvant chemotherapy 57 radiation chemoradiation 57 sorafenib Nexavar 57 NeoVisc 57 EndoTAGTM 1 57 standard chemotherapy regimen 57 standard chemotherapy regimens 57 Barocycler instruments 57 oxycodone CR 57 AGILECT R 57 mCRPC 57 continuingoperations 57 chemoradiation therapy 57 q#h 57 PSADT 57 BUPHENYL R 57 low dose cytarabine 57 ECU netbacks 57 platinum refractory 57 Taxol ® 57 trastuzumab Herceptin R 57 FOLFOX4 57 Orally administered 57 Craftmade segment 57 dasatinib Sprycel 57 docetaxel Taxotere ® 57 IV bolus 57 relapsed CLL 57 recurrent GBM 57 PegIFN RBV 57 erlotinib Tarceva ® 57 BCG refractory 57 FluCAM 57 EGFR TKI 57 recurrent glioblastoma multiforme 57 Pharmacokinetic parameters 57 vinorelbine 57 ratio ICER 57 morphometric vertebral fractures 57 alkylating agent 57 Capecitabine 57 iniparib BSI 57 Polyurethanes segment 57 antiangiogenic therapy 57 metastatic malignant melanoma 57 follicular lymphomas 57 alpha interferons 57 folinic acid 57 TEUR -# 57 FOLFOX regimen 57 Free Survival PFS 57 Copegus ribavirin 57 Platelet counts 57 refractory NSCLC 57 prokinetic agent 57 cyclophosphamide chemotherapy 57 MoxDuo TM IR 57 panitumumab Vectibix 57 infliximab monotherapy 56 plus dexamethasone 56 APTIVUS r 56 DexaSite 56 oral Hycamtin 56 radiation sensitizer 56 MARRIOTT REVENUES totaled 56 thrombopoietin TPO 56 relapsed ovarian cancer 56 gemcitabine Gemzar 56 placebo intravenously 56 calcineurin inhibitor 56 3D conformal radiation 56 NMIBC 56 Tarceva erlotinib 56 bone grafting procedures 56 Plasma Proteins 56 Femara letrozole 56 recurrent metastatic 56 Faslodex 56 aromatase inhibitor AI 56 Xeloda ® 56 FIRMAGON 56 gemcitabine chemotherapy 56 IV NSCLC 56 squamous cell carcinoma SCC 56 ONCASPAR 56 Taxotere ® 56 bendamustine 56 urethral bulking agent 56 IFN alfa 56 TTF Therapy 56 demonstrated antitumor activity 56 lintuzumab SGN 56 LHRH analogues 56 Halotron revenues 56 Wireline adjusted EBITDA 56 Flu Cy 56 #QCY# [001] 56 oral picoplatin 56 TKI therapy 56 FHLB advances decreased 56 gallium arsenide GaAs substrate 56 daunorubicin 56 relapsed refractory multiple myeloma 56 AbD Serotec segment 56 Abelcet 56 #compared 56 Rigid PCB shipments 56 Clindamycin 56 idarubicin 56 ninemonths 56 Filgrastim 56 HBeAg + 56 Mg Uk 56 cefuroxime 56 metastatic malignant 56 ended September# 56 mTOR inhibitors 56 doxorubicin HCl liposome injection 56 epothilone KOS 56 3TC lamivudine 56 revascularized 56 Zemplar 56 VANTAS R 56 H1 FY# [002] 56 miconazole Lauriad ® 56 microtubule inhibitor 56 pegylated interferons 56 taxane 56 laparoscopically assisted 56 taxane therapy 56 BD Biosciences segment 56 oral chemotherapeutic agent 56 BUPHENYL R sodium phenylbutyrate 56 null responder 56 #.#bn rub [003] 56 Gemzar gemcitabine 56 somatostatin analog 56 ductal cancer 56 rituximab Rituxan 56 liver metastasis 56 nine monthsended 56 Radical prostatectomy 56 orally administered inhibitor 56 diameter stenosis 56 LIALDA MEZAVANT 56 intravesical infusion therapy 56 superficial basal cell carcinoma 56 PENTASA 56 carboplatin chemotherapy 56 Toxicities 56 NutropinAq ® 56 dalteparin 56 % miconazole nitrate 56 Ribavirin royalties 56 4mg/kg 56 MAGE A3 ASCI 56 iniparib 56 dasatinib Sprycel ® 56 Phosphates segment 56 Metastatic breast cancer 56 untreated multiple myeloma 56 mRCC 56 CRp 56 VALSTAR 56 #mg dose [002] 56 tumor regressions 56 remission induction 56 comparedto 56 plus prednisone 56 intrinsic sphincter deficiency 56 vinca alkaloids 56 TKB# 56 assessing T DM1 56 docetaxel 56 Noninterest Expense Noninterest expense 56 Cardiac Surgery Systems 56 CLL SLL 56 Natalizumab 56 biochemical relapse 56 #mg/m# [001] 56 contralateral breast 56 cytarabine daunorubicin 56 antiretroviral naïve 56 Zorbtive TM 56 alefacept 56 nilotinib Tasigna ® 56 Bilive 56 hormone receptor negative 56 YONDELIS 56 mg/m2 cohort 56 NRTI backbone 56 malignant pleural mesothelioma 56 pegylated interferon alfa 56 cediranib 56 Nascobal 56 unresectable HCC 56 chemotherapy docetaxel 55 NovoSeven ® 55 cutaneous squamous cell carcinoma 55 Aptivus ® 55 Hepatocellular Carcinoma HCC 55 calcineurin inhibitors 55 external beam radiotherapy 55 pomalidomide 55 intravenous cyclophosphamide 55 irinotecan cisplatin 55 PRAVACHOL R 55 axitinib 55 Orthovisc R 55 targeted radiotherapeutic 55 underwent resection 55 NanoKnife IRE System 55 VISICOL 55 Topotecan 55 Surfactant gross 55 taxane chemotherapy administered 55 lenalidomide dexamethasone 55 caspofungin 55 #bps qoq [001] 55 galiximab 55 relapsed multiple myeloma 55 clinicopathological features 55 Visiting Nurse VN 55 adjuvant tamoxifen 55 cyclophosphamide doxorubicin vincristine 55 nucleoside analog 55 Noninterest expense totaled 55 Fulvestrant 55 adjuvant cisplatin 55 Mg Usa 55 metastatic gastric 55 Valacyclovir 55 motesanib 55 CYPHER Stent 55 heavily pretreated patients 55 RLEC adjusted EBITDA 55 DOXIL 55 resistant hormone refractory 55 ceftazidime 55 doxercalciferol 55 adjuvant radiotherapy 55 dental reconstructive 55 ZANAFLEX CAPSULES 55 hepatoma 55 liposomal formulation 55 everolimus eluting stents 55 tinidazole 55 fallopian tube cancers 55 Kivexa 55 refractory ovarian cancer 55 ® bortezomib 55 gefitinib Iressa 55 Platinol 55 Forlax R 55 basal cell carcinoma BCC 55 placebo PBO 55 mycophenolate mofetil 55 HBeAg seroconversion 55 cytoreduction 55 Amgen Neulasta R 55 resectable 55 TORISEL 55 aspirin clopidogrel 55 expenses totaled Ps 55 3TC lamivudine Epivir 55 topical ophthalmic 55 immunomodulatory therapy 55 Infergen R 55 evaluating Xcytrin 55 Gross Margin Gross 55 surgical excision 55 interferon alfa 55 abacavir lamivudine 55 baseband semiconductors 55 enzastaurin 55 anincrease 55 zoledronate 55 quarter# 55 SUPPRELIN R LA 55 cisplatin gemcitabine 55 Dal Tile segment 55 Operative mortality 55 capecitabine Xeloda 55 interferon ribavirin 55 pancreatic insufficiency 55 Byproduct revenues 55 R sevelamer hydrochloride 55 doxorubicin docetaxel 55 MabCampath 55 Hönle Group 55 Lead Fabricating 55 androgen suppression 55 EDITDA 55 R emtricitabine 55 Vidaza R 55 clinically contraindicated 55 ® lenalidomide 55 Residential Furnishings 55 Adjusted EBITDA1 55 Ginkor Fort ® 55 Erbitux cetuximab 55 Taxol paclitaxel 55 chemoradiotherapy 55 Adhesive Dispensing segment 55 Scantron segment decreased 55 Q#/# EUR [002] 55 administered subcutaneously 55 Trastuzumab 55 AmBisome 55 Maxipime 55 liver metastases 55 HGS# 55 Cytoxan 55 TPIAO 55 Torisel 55 corticosteroid dexamethasone 55 benign prostatic hyperplasia enlarged 55 Tacrolimus 55 Epirubicin 55 docetaxel Taxotere R 55 lopinavir r 55 GuideLiner catheter 55 Blended ASP 55 piperacillin 55 topotecan 55 mitoxantrone 55 Bezielle 55 adjuvant radiation 55 capecitabine Xeloda ® 55 Adjusted Ebitda 55 TNF inhibitor 55 EBRT 55 Leucovorin 55 candidates Azedra TM 55 shippable backlog 55 paclitaxel Taxol 55 sargramostim 55 systemic ALCL 55 Aprovel R 55 offiscal 55 endocrine therapies 55 nalbuphine ER 55 fenofibrates 55 radical nephrectomy 55 Kronos TiO2 production 55 basal insulins 55 tazarotene 55 -#.# Mio 55 Q2 FY# [001] 55 taxotere 55 INEGY 55 biochemical recurrence 55 Mitoxantrone 55 Megace R ES 55 leukemia AML 55 ® natalizumab 55 surgical resection cavity 55 Medication Delivery 55 Bacillus Calmette Guerin BCG 55 lanreotide 55 Enventis Sector 55 benign nodules 55 fluorouracil 55 colorectal cancer liver metastases 55 uric acid lowering 55 SEK#.#bn [002] 55 pegylated liposomal doxorubicin PLD 55 infusional 55 diagnosed GBM 55 nausea dehydration dyspnea 55 resectable pancreatic cancer 55 muscle relaxant Amrix 55 5 Fluorouracil 55 Custom folding carton 55 Taxotere chemotherapy 55 Gross Profit Gross 54 Degarelix 54 bone metastasis 54 Telintra 54 humanised monoclonal antibody 54 relapsed SCLC 54 operatingincome 54 sulphate producing 54 graft occlusion 54 Evaporative Cooling segment 54 rilonacept Injection 54 Explosive Metalworking segment 54 nonmetastatic 54 Neupogen ® 54 taxane resistant 54 was#.# 54 trans retinoic acid ATRA 54 Hazard Ratio 54 Campath alemtuzumab 54 embolics 54 blastic phase 54 definite stent thrombosis 54 nilotinib Tasigna 54 noninvasive outpatient 54 pegylated alpha interferon 54 ovarian carcinoma 54 endoscopic remission 54 ASUR regulated 54 fullyear outturn represents 54 IMC A# 54 LHRH receptor positive 54 DiaMed acquisition 54 Adjusted EBITA 54 nodal metastasis 54 #.#bn rub [004] 54 visilizumab 54 Q3 FY'# 54 SBS Balancer segment 54 comparedwith 54 coronary stenting 54 paclitaxel cisplatin 54 TMP SMX 54 herpetic keratitis 54 Fab 3E 54 total thyroidectomy 54 ® tenofovir disoproxil 54 dexamethasone VAD 54 bevacizumab Avastin R 54 totaled EUR#.# 54 PEGINTRON TM 54 Vfend 54 #.# crores [002] 54 HbA 1c levels 54 Xelox 54 curative resection 54 BCG refractory carcinoma 54 Klean Prep TM 54 adjusted1 54 mycophenolic acid 54 glycosylated hemoglobin levels 54 FHLB borrowings decreased 54 xenograft models 54 evaluating picoplatin 54 Bevacizumab Avastin 54 estrogen receptor antagonist 54 IV Infusion Therapy 54 LFQ gross 54 millioncompared 54 cidofovir 54 EARNINGS IN RETROSPECT 54 non resectable 54 thequarter 54 boosted protease inhibitor 54 oral levofloxacin 54 RAPTIVA r 54 NEUPOGEN 54 azathioprine 54 receiving highly emetogenic 54 FUEL CHEM segment 54 Capesaris 54 Smecta ® 54 #.# Crores [003] 54 preoperative radiotherapy 54 LOVENOX R 54 peritoneal carcinomatosis 54 hepatitis B immune globulin 54 evaluating satraplatin 54 OZURDEX ® 54 radioiodine therapy 54 Printed Circuit Materials 54 conventional DMARDs 54 transarterial 54 orally bioavailable mimics 54 Posaconazole 54 adriamycin 54 multitargeted 54 medically inoperable 54 ASCT 54 subcutaneously administered 54 unresectable stage 54 Amgen Neulasta ® 54 mg m² 54 overlapping toxicities 54 refractory chronic lymphocytic 54 noninterest expense totaled 54 GYN Surgical 54 gastrointestinal stromal tumors GIST 54 tigecycline 54 SmartGrowth Deposits 54 IVUS disposable 54 esophageal resection 54 Isomedix Services 54 ß blockers 54 cisplatin carboplatin 54 Median progression 54 Revlimid lenalidomide 54 Seroquel quetiapine fumarate 54 ritonavir boosted 54 DMARDS 54 AmericanSingles segment 54 via intradermal injections 54 Navelbine 54 nicardipine 54 rimonabant #mg 54 2Q FY# [001] 54 recombinant follicle stimulating 54 interferon alfa 2b 54 mycophenolate mofetil MMF 54 CYP#A# substrate 54 oral prednisolone 54 Churn Rate 54 COLAZAL R 54 Oxaliplatin 54 metastatic HER2 positive 54 PEG IFN 54 stage IIIB IV 54 DAS# remission 54 HBeAg positive 54 temsirolimus 54 metformin sulfonylurea 54 IMiDs ® compound 54 irinotecan doxorubicin oxaliplatin paclitaxel 54 dosing cohorts 54 upholstery fabrics segment 54 adjusted2 54 renal cell carcinomas 54 Summarized consolidated 54 Naive Patients 54 gefitinib 54 ixabepilone 54 Daptomycin 54 oral rivaroxaban 54 Gleevec resistant 54 Specialty Chemicals Segment 54 bps YoY 54 Rituxan rituximab 54 Flow NIW 54 antimetabolite 54 EBITDAO 54 metastatic GIST 54 XAGRID 54 hepatorenal syndrome 54 mCi kg 54 chemotherapy FOLFOX 54 sunitinib 54 #mg/m# [002] 54 mCRC patients 54 paroxysmal AF 54 abiraterone acetate 54 radiofrequency ablation RFA 54 advanced unresectable 54 SEK#.#m [001] 54 earnings pershare 54 pancreatic adenocarcinoma 54 Scrap intake 54 R adefovir dipivoxil 54 prior nephrectomy 54 MVAS gross 54 leukemia APL 54 levosimendan 54 ascompared 54 darbepoetin alfa 54 rituximab Rituxan ® 54 Fine Chemicals segment 54 Zometa hazard 54 myelodysplastic myeloproliferative diseases 54 indolent NHL 54 chemoradiation 54 refractory myeloma 54 cisplatin resistant 54 Seamap equipment 54 KRAS mutant 54 EBITD 54 postoperative mortality 54 histologically confirmed 54 diagnosed multiple myeloma 54 Vacation Interval sales 54 #Gy 54 Paraplatin ® 54 advanced HER2 positive 54 PEG interferon 54 doxazosin 54 amphotericin B 54 cetuximab Erbitux 54 cytidine nucleoside analog 54 superficial bladder cancer 54 operating EBIDA 54 Chemophase 54 Lucentis injections 54 LOE decreased 54 #.#g/day 54 sorafenib 54 thoracoscopic lobectomy 54 serum urate 54 salpingo oophorectomy 54 R tenofovir disoproxil 54 PMPS brand 54 mg p = 53 CsA 53 peak plasma concentrations 53 CIN3 53 AstraZeneca Toprol XL 53 #.Net 53 MoxDuo IR 53 Vinorelbine 53 peginterferon 53 #bps YoY [002] 53 insulin analogues 53 #mg ATC 53 plus dacarbazine 53 carmustine 53 antiandrogens 53 #mg/#mg 53 Dabigatran etexilate 53 lipid lowering medications 53 Prepaid ARPU 53 Sees FY# revs 53 Fully diluted EPS 53 sequential 53 verum acupuncture 53 Euro Libor #.# 53 Etoposide 53 EPOGEN 53 subcutaneous enoxaparin 53 Temodar ® 53 Vidaza ® 53 EDEMA3 trial 53 Tarvacin Anti Cancer 53 #MFY# [001] 53 tramadol ER 53 Roche Herceptin 53 heavily pretreated 53 EBDITA 53 Benazepril 53 proforma revenues 53 cystectomy 53 non myeloid malignancies 53 Interest Expense Interest expense 53 VIDAZA 53 edaravone 53 liposomal amphotericin B 53 5 FU leucovorin 53 partial remissions 53 ribavirin RBV 53 timepoints 53 Sandostatin R 53 adjuvant trastuzumab 53 spinal stimulation 53 divalproex sodium 53 ICS LABA combination 53 sumatriptan succinate 53 non squamous histology 53 Revenue Trades DARTs 53 ofapproximately 53 Retail Leathercraft posted 53 USD#.#m [007] 53 unfractionated heparin UFH 53 GW# [003] 53 generation purine nucleoside 53 5 fluorouracil leucovorin 53 Munghana Lonene Listenership 53 adjusted Ebitda 53 malfunctioning pacemakers 53 cefdinir 53 interstitial brachytherapy 53 GBP #.#m [003] 53 bevacizumab Avastin ® 53 Fluorouracil 53 FQ = fiscal 53 MNOK #.# 53 Soft Tissue Sarcoma 53 Doxil 53 oral vancomycin 53 ferroalloy segment 53 extracapsular extension 53 Zevalin consolidation 53 Azacitidine 53 MAKOplasty procedures 53 plus gemcitabine 53 PTOI 53 FTE staffing 53 stage IIIA 53 agalsidase alfa 53 CSDs Dr Pepper 53 marketed workover rigs 53 malignancy HCM 53 Prograf ® 53 chemotherapeutic regimens 53 Gliadel 53 Dispensing Equipment 53 1Q FY# 53 PET resin imports 53 HY# 53 erectile restoration 53 Engineered Materials segment 53 imatinib Gleevec ® 53 TURBT 53 postintervention 53 Carboplatin 53 Repliform R revenues 53 Newsstand Distribution Services 53 macrolide antibiotics 53 VersaFilm 53 Peginterferon 53 microgram kg 53 tamoxifen Nolvadex ® 53 pemetrexed Alimta 53 Luminex NASDAQ LMNX 53 subcutaneous SC 53 sustained virological response 53 dose melphalan 53 ovarian suppression 53 Wafer shipments 53 Newsprint expense 53 HERCEPTIN 53 dornase alfa 53 Licorice Products segment 53 Panzem NCD 53 median survivals 53 targets EpCAM expressing 53 EGFR tyrosine kinase inhibitor 53 vincristine adriamycin 53 Noninterest expense decreased 53 Imiquimod 53 IFL chemotherapy regimen 53 ADP receptor antagonist 53 postpaid subscriber base 53 chemotherapy gemcitabine 53 efavirenz EFV 53 redesigned Elantra performed 53 pegylated interferon alfa 2a 53 Mechatronics Division 53 fluorouracil leucovorin 53 voriconazole 53 sequential basis 53 radical prostatectomy RP 53 Rs.#.#cr 53 anti androgen 53 Mainline RPMs 53 Copart NASDAQ CPRT 53 GlaxoSmithKline Zofran 53 ¥ #.#tr 53 pazopanib 53 transplantation HCT 53 evaluating T DM1 53 EBITDAA